ALK testing in lung adenocarcinoma: Technical aspects to improve FISH evaluation in daily practice

Journal of Thoracic Oncology

Volumn 10, Issue 4, 2015, Pages 595-602

  Martin, Vittoria ^a   Bernasconi, Barbara ^b   Merlo, Elisabetta ^a   Balzarini, Piera ^c   Vermi, William ^c   Riva, Alice ^a   Chiaravalli, Anna Maria ^b   Frattini, Milo ^a   Sahnane, Nora ^b   Facchetti, Fabio ^c   Mazzucchelli, Luca ^a   Sessa, Fausto ^b   Tibiletti, Maria Grazia ^b  

^a INSTITUTE OF PATHOLOGY   (Switzerland)

^b OSPEDALE DI CIRCOLO   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

ALK; ALK inhibitor; Fluorescence in situ hybridization; Lung cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; DNA; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; CANCER PATIENT; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ASSAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE REARRANGEMENT; GOLD STANDARD; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; TISSUE SECTION; ADENOCARCINOMA; CLINICAL TRIAL; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; RETROSPECTIVE STUDY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DNA, NEOPLASM; FEMALE; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 84938287116     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000444     Document Type: Article

References (30)

1. Shaw AT, Solomon B, Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011 17 2081 2086
2. Camidge DR, Bang YJ, Kwak EL, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012 13 1011 1019
3. FDA Approves Xalkori with Companion Diagnostic for a Type of Late- Stage Lung Cancer United States Food and Drug Administration. 2011. Available at: http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm270058.htm. Accessed October 2014
4. EMA Authorisation: Xalkori is approved for use in the European Union. Available at: http://www.ema.europa.eu/ema/index.jspcurl=pages/medicines/human/medicines/002489/human-med-001592.jsp&mid=WC0b01ac058001d124. Accessed October 2014
5. Palmer RH, Vernersson E, Grabbe C, Hallberg B, Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 2009 420 345 361
6. Soda M, Choi YL, Enomoto M, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007 448 561 566
7. Sasaki T, Rodig SJ, Chirieac LR, Jänne PA, The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010 46 1773 1780
8. Savic S, Bode B, Diebold J, Detection of ALK-positive non-small-cell lung cancers on cytological specimens: high accuracy of immunocytochemistry with the 5A4 clone. J Thorac Oncol 2013 8 1004 1011
9. Schildhaus HU, Deml KF, Schmitz K, Chromogenic in situ hybridization is a reliable assay for detection of ALK rearrangements in adenocarcinomas of the lung. Mod Pathol 2013 26 1468 1477
10. Cutz JC, Craddock KJ, Torlakovic E, Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer. J Thorac Oncol 2014 9 1255 1263
11. Zhang YG, Jin ML, Li L, Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-Time quantitative RT-PCR on paraffin-embedded tissues. PLoS One 2013 8 e64821
12. Solomon B, Varella-Garcia M, Camidge DR, ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 2009 4 1450 1454
13. Kwak EL, Bang YJ, Camidge DR, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010 363 1693 1703
14. Weickhardt AJ, Aisner DL, Franklin WA, Varella-Garcia M, Doebele RC, Camidge DR, Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer 2013 119 1467 1477
15. Shaw AT, Yeap BY, Mino-Kenudson M, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009 27 4247 4253
16. Rodig SJ, Mino-Kenudson M, Dacic S, Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009 15 5216 5223
17. Thunnissen E, Bubendorf L, Dietel M, EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch 2012 461 245 257
18. Marchetti A, Ardizzoni A, Papotti M, Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology. J Thorac Oncol 2013 8 352 358
19. The European Society of Pathology (ESP) established an EQA program for testing biomarker mutations in non-small cell lung carcinoma (NSCLC). Available at: http://lung.eqascheme.org/info/public/alk/index.xhtml. Accessed October 2014
20. Camidge DR, Kono SA, Flacco A, Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010 16 5581 5590
21. Camidge DR, Skokan M, Kiatsimkul P, Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy. Cancer 2013 119 3968 3975
22. Sahnane N, Gueli R, Tibiletti MG, Pyrosequencing for EGFR mutation detection: diagnostic accuracy and clinical implications. Diagn Mol Pathol 2013 22 196 203
23. Pao W, Miller V, Zakowski M, EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004 101 13306 13311
24. Salido M, Pijuan L, Martínez-Avilés L, Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol 2011 6 21 27
25. Marchetti A, Barberis M, Papotti M, ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first Italian external quality assurance scheme. J Thorac Oncol 2014 9 1470 1476
26. Savic S, Bubendorf L, Role of fluorescence in situ hybridization in lung cancer cytology. Acta Cytol 2012 56 611 621
27. Conde E, Angulo B, Izquierdo E, The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre. Histopathology 2013 62 609 616
28. Minca EC, Lanigan CP, Reynolds JP, ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material. J Thorac Oncol 2014 9 464 468
29. Le Quesne J, Maurya M, Yancheva SG, A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material. J Thorac Oncol 2014 9 769 774
30. Zhou J, Zhao J, Sun K, Accurate and economical detection of ALK positive lung adenocarcinoma with semiquantitative immunohistochemical screening. PLoS One 2014 9 e92828